“The Oxford vaccine is… striking, since the point was to pay researchers, but not to rely on patent monopolies to generate large profits.” – Economist Dean Baker
The world is abuzz today after a team of medical researchers from Oxford University in the United Kingdom announced that advanced trials of their experimental coronavirus vaccine were a roaring success, with the vaccine possibly being rolled out before Christmas. Testing was done on 24,000 volunteers in the U.K, Brazil, and South Africa, with an average effectiveness of over 70%. However, when the vaccine was administered as a half dose, then patients were later given a full one, effectiveness increased to 90%. Encouragingly, there were no serious side effects registered among any of the volunteers, none of whom had to go to the hospital as a result of being immunized. The U.K. government has already ordered 100 million doses.
3 comments:
Doesn’t sound like these Oxford people are going to use messenger RNA to replicate just the spike protein like Pfizer and Moderna...
Maybe those two are better technology so they may cost a few dollars more than the Oxford thing.. so what...
Pfizer is the go-to vaccine for people living 70 degrees north of the Earth's equatorial plane, or something like that.
One pandemic every two years should keep their bottom line nice & healthy.
Post a Comment